Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 Study

Princeton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel anticonvulsant compound, has completed the first stage of pivotal IND-enabling Tox studies in rodent and non-rodent species.

“The recent results confirm what we already know about this exciting compound,” said Pawel Zolnierczyk, CEO. “We’re one step closer to bringing this effective therapeutic to a clinic trial, with the potential to significantly improve patients’ quality of life. Results of recent toxicological studies show that iQ-007 unique mechanism of action as a Positive Allosteric Modulator (PAM) of the EAAT2 neurotransporter, is a very promising therapeutic strategy, ‘triggering a human natural safety mechanism’ that allows for more efficient clearance of excess glutamate which in turn prevents neurotoxicity and seizures.”

iQ-007 is well tolerated and continues to demonstrate an impressive safety profile. iQure Pharma is looking forward to completing the IND-enabling tox study series, which will accelerate the preparation of the First in Human Phase 1 study.

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.

For more information, please contact pawel.zolnierczyk@iqurepharma.com.

iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic Pain

Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel analgesic compound dedicated to treating neuropathic pain, has been awarded a patent.

“We are thrilled with the patent granted for iQ-008,” said iQure Chief Executive Officer Pawel Zolnierczyk.  “This is an important step in the process of commercializing this promising asset for the treatment of Pain. Patent protection is pivotal to maintaining the value of our assets. With the awarding of this patent, we have expanded its protection and strengthened its potential on the market.”

iQ-008 is effective in critical in vivo studies against the “gold-standard,” but without the typical CNS side effects. Through its unique mechanism, focused on simultaneous action on more than one pain relevant molecular target, iQ-008 displays strong efficacy with minimal risk of side effects. The compound is also being vigorously tested by the NIH in its high profile Preclinical Screening Platform for Pain (PSPP), as part of the HEAL Initiative.

iQure researchers developed iQ-008 as a therapeutic for neuropathic pain, in response to the more than 25 million Americans who live with chronic pain and are forced to rely solely on potentially addictive opioid medications for pain management.

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.

For further information, please contact pawel.zolnierczyk@iqurepharma.com.

iQure Pharma Attending JPM Week in San Francisco — January 8-12, 2024

Princeton, NJ, December 22, 2023 ─ iQure Pharma Inc. (iQure), a U.S.-based pre-clinical drug discovery company focusing on central nervous system (CNS) disorders, is attending the 42nd Annual J.P. Morgan Health Care Conference, JPM Week, in January 2024.

iQure’s portfolio of treatments in Epilepsy, Pain and other neurodegenerative diseases has had a number of positive developments in the last year. As a result, iQure Pharma has intensified its focus in the areas of strategic partnering and fundraising, targeting clinical development of iQ-007 in 2024. Pawel Zolnierczyk, CEO and Henk de Wilde, COO and R&D Director, will be participating in JPM Week to further explore strategic collaborations with pharma and expand current fundraising activities.

“These are exciting times for iQure with very promising market traction and significant interest from pharma for both of our assets,” said iQure CEO Pawel Zolnierczyk. “The recent oversubscription of our Series A round, validates iQure Pharma’s innovative approach to glutamate clearance. We remain dedicated to our mission of improving lives of patients living with neurological conditions.”

iQure's leading compound, iQ-007, is a neuromodulator targeting toxic levels of glutamate in the synaptic cleft. An elevated level of glutamate leads to neurotoxicity and ultimately to neural degeneration. iQ-007 operates by a Positive Allosteric Modulation of Excitatory Amino Acid Transporter 2 (EAAT2 PAM), which is responsible for up to 90% of glutamate uptake. The company’s pioneering glutamate clearance platform is expected to foster the development of new treatments for a wide range of neuro disorders, including epilepsy, stroke, neuropathic pain, Parkinson’s, Alzheimer’s, and Traumatic Brain Injury. These treatments are aimed at delivering effective solutions without the common side-effects associated with CNS therapeutics.

For those interested in meeting with iQure Pharma in San Francisco during JPM Week, please register here:

iQure Pharma at 2024 JPM BIO Partnering

About iQure Pharma:

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.